On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Legal
-
-
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On June 14, 2018, Senator Orrin Hatch of Utah, the co-author of the Hatch-Waxman Act, filed an amendment to the Hatch-Waxman Act in an...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 8, 2018, Amgen Inc. (“Amgen”) filed suit against Adello Biologics, LLC (“Adello”) in the District of New Jersey, alleging...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we recently covered, May 15, 2018, saw the FDA granting approval to Hospira (now a Pfizer subsidiary) for its Retacrit injection, a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, the Federal Circuit affirmed a lower court’s dismissal of AbbVie’s complaint seeking declaratory judgment of invalidity of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]